Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
Crossref DOI link: https://doi.org/10.1007/s10096-018-3410-8
Published Online: 2018-11-08
Published Print: 2019-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vehreschild, Maria J. G. T.
Taori, Surabhi
Goldenberg, Simon D.
Thalhammer, Florian
Bouza, Emilio
van Oene, Joop
Wetherill, Graham
Georgopali, Areti
Text and Data Mining valid from 2018-11-08
Article History
First Online: 8 November 2018